Penwest Pharmaceuticals Co.
Records under this name other than patents Penwest Pharmaceuticals Co. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Penwest Pharmaceuticals Co.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,394,812 | Sustained Release Formulations of Nalbuphine Formerly held In force · High confidence | In force | High confidence | |
| US 8,771,732 | Sustained release formulations of nalbuphine Formerly held In force · High confidence | In force | High confidence | |
| US 8,765,175 | Sustained Release Formulation of Nalbuphine Formerly held Term ended Term ended Aug 24, 2026 · High confidence | Term ended | Term ended Aug 24, 2026 | High confidence |
| US 9,186,330 | Sustained Release Formulation of Nalbuphine Formerly held Term ended Term ended Aug 24, 2026 · High confidence | Term ended | Term ended Aug 24, 2026 | High confidence |
| US 9,351,938 | Sustained Release Formulation of Nalbuphine Formerly held Term ended Term ended Aug 24, 2026 · High confidence | Term ended | Term ended Aug 24, 2026 | High confidence |
| US 10,172,798 | Sustained Release Formulation of Nalbuphine Formerly held Term ended Term ended Aug 24, 2026 · High confidence | Term ended | Term ended Aug 24, 2026 | High confidence |
| US 7,214,387 | Sustained Release Formulations of Metformin Formerly held Term ended Term ended May 10, 2025 · High confidence | Term ended | Term ended May 10, 2025 | High confidence |
| US 7,276,250 | Sustained Release Formulations of Oxymorphone Formerly held Term ended Term ended Feb 4, 2023 · High confidence | Term ended | Term ended Feb 4, 2023 | High confidence |
| US 8,389,008 | Delayed Release Dosage Forms Formerly held Term ended Term ended Jul 11, 2022 · High confidence | Term ended | Term ended Jul 11, 2022 | High confidence |
| US 8,679,535 | Sustained Release Matrix Systems for Highly Soluble Drugs Formerly held Lapsed on the fee record Ended Mar 25, 2022 · Medium confidence | Lapsed on the fee record | Ended Mar 25, 2022 | Medium confidence |